A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa by Hopkins, M E et al.
A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa

Michael E Hopkins MBChB MRCS (ENT) – ENT Department, NHS Lothian

Alex Bennett MBBS, DLO, FRCS (ORL-HNS), Med – ENT Department, NHS Lothian

Naomi Henderson MBChB MSc  FRCPath MRCP(UK) – Department of Microbiology, NHS Lothian

Karen F Macsween MD FRCPath MRCP(UK) – Department of Microbiology, NHS Lothian

David Baring MBBS, FRCS (ORL-HNS) – ENT Department, NHS Lothian

Rebecca Sutherland FRCP – Department of Infectious Diseases, NHS Lothian


Lead Author: Michael E Hopkins. ENT Department, NHS Lothian, Lauriston Buildings, Lauriston Place, EH3 9DE	michael.hopkins6@nhs.net

This paper was presented as a poster at the ENT UK Annual meeting in September 2019 at Grand Connaught Rooms. It was awarded the accolade of ‘Best Poster’



Abstract:

Background 
Necrotising otitis externa (NOE) is a progressive infection of the external auditory canal which extends to affect the temporal bone and adjacent structures. Progression of disease process can result in serious sequelae including cranial nerve palsies and death. There is currently no formal published treatment guideline.
Aims
To integrate current evidence and data from our own retrospective case series to develop a guideline to optimise NOE patient management
Methods
A retrospective review of NOE cases within NHS Lothian between 2013-2018 was performed along with a PubMed review.
Results
Prevalent presenting signs, symptoms and patient demographic data were established. Furthermore, features of cases associated with adverse outcomes were defined. A key feature of the guideline is defining at-risk patients with initial intensive treatment. Investigations and outcomes are assessed and treatment adjusted appropriately.
Conclusion
This multi-departmental approach has facilitated the development of a succinct, systematic guideline for the management of NOE. Initial patient outcomes appear promising.
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Introduction
Necrotising otitis externa (NOE) is a progressive infection of the external auditory canal which extends to affect the temporal bone and adjacent structures. This invasive infection originates between the cartilaginous and bony portions of the external auditory canal. The most common causative organism is Pseudomonas aeruginosa. The infection begins as an otitis externa that progresses into osteomyelitis of the temporal bone. Once infection and subsequent granulation occurs over the osseous canal, the VIIth cranial nerve can become compromised, resulting in a facial nerve palsy. If infection progresses to the base of skull, cranial nerves IX,X,XI and XII can be affected, resulting in dysphagia, hoarseness, weakness of the shoulder and difficulty in swallowing. Therefore, if inadequately treated, this disease is associated with significant morbidity and mortality. If at risk patients are identified early and treated adequately then improved outcomes can be achieved.

There is currently no formal published guideline on the treatment of NOE. This is likely to be as a result of the heterogeneous nature of its presentation and progression as well as contention amongst health professionals regarding its diagnosis. The authors’ aim was to incorporate salient points from the evidence base, as well as our practice, in the diagnosis and management of NOE. We have also advocated a multi-specialty approach including input from Ear, Nose and Throat (ENT) surgeons, infectious disease specialists, microbiologists, diabetes specialists (when applicable) and neuroradiologists with the intention of producing a guideline which is consulted by all the specialties involved in treating this condition.  

NOE is certainly an increasing health burden, with incidence throughout the UK rising. Data from NHS National Services Scotland confirms an increase in cases from 0.2 cases per 100,000 in 2008 to 1.19 cases per 100, 000 in 2018 (ISD Scotland, direct communication). This is based on patients who are discharged from hospital with a diagnosis of necrotising otitis externa, and may underestimate the true incidence. 

Most departments advocate prolonged courses of intravenous antibiotics which may necessitate a lengthy hospital stay. There is a growing body of evidence outlining demographic features of patients suffering from NOE which includes a preponderance towards elderly, diabetic males1. With an aging population it is therefore not surprising that the incidence is on the rise. A combination of increased age and diabetes predispose patients to microvascular abnormalities around the ear canal. Furthermore, pseudomonal infection in this environment can result in a surrounding vasculitis with thrombosis and coagulation necrosis of surrounding tissue2. Cerumen of diabetic patients is speculated to have a higher pH making it more susceptible to bacterial growth.

Materials and Methods
A retrospective review of NOE cases within NHS Lothian was undertaken, inclusive of dates April 2013 to January 2018. Clinical coding data based on the International Classification of Disease (ICD) code at discharge or death was used to extract cases for review. Here, we focused on presenting signs and symptoms, patient demographics, type and timing of investigations, organism identified, management instigated and patient outcome in order to identify trends.

We also undertook a review of the current literature using a Pubmed search to substantiate findings from our own data and generate an evidence-based guideline. The search terms used were ‘malignant otitis externa’, ‘necrotising otitis externa’ and ‘skull base osteomyelitis’. 

Following implementation of our guideline, data were then collected prospectively on all patients presenting with clinical signs of NOE, that subsequently underwent investigation, allowing assessment of its impact on management and outcomes of this patient cohort.

Results and Analysis

Twenty patients were identified in our search. On review of presenting signs and symptoms, 100% (20/20) of patients with radiologically proven NOE suffered from otalgia and 95% (19/20) suffered purulent otorrhoea. Eighty-five percent (17/20) demonstrated polypoidal granulation tissue within the external auditory canal. Twenty-five percent (5/20) suffered from cranial nerve palsies, most commonly the facial nerve, with two thirds of these established on presentation (Table I).
Analysis of patient demographics established that 65% (13/20) were diabetic, and of the non-diabetic group (n=7), 71% (5/7) had previous ear surgery and 1/7 suffered from systemic immunosuppression (14%) (Table II). Eighty-five percent (17/20) were over the age of 65 years. 
Regarding investigation findings, Pseudomonas aeruginosa was cultured in 60% (12/20), Staphylococcus aureus was cultured in 25% (5/20), in 83% of cases where Ps.aeruginosa  was cultured, the organism was susceptible  to ciprofloxacin. Aspergillus flavus was isolated from one patient (5%), however, this was not initially targeted in treatment (Table III). C-Reactive protein was reviewed and this ranged from 9 to 137 mg/l at diagnosis with no demonstrable link to patient outcome. Computed Tomography (CT) scanning was used for diagnosis in 100% of cases, Magnetic Resonance Imaging (MRI) was used as an adjunct in 35% (7/20).
In treating the condition, systemic ciprofloxacin was the most widely used antibiotic, prescribed in 60% (12/20) of cases. Other courses include 15% (3/20) patients who received meropenem, 5% (1/20) that received piperacillin-tazobactam and 10% (2/20) that received piperacillin-tazobactam followed by meropenem. 
Twenty-five percent of patients (5/20) in our retrospective audit demonstrated a deterioration in their condition under treatment from our service. This is a relatively high proportion and on review, the reasons for the observed deterioration included two delayed diagnoses, and under treatment from ENT, one inadequate course length, one possible missed fungal infection and 3 patients deteriorated on a course of oral ciprofloxacin without having received intravenous antibiotics.
Only 1 case out of 20 relapsed following completion of treatment during the study period. 

Discussion and Guideline Development 

Figure I. – Image of flow chart

The first step in our guideline (Figure 1) is identifying patients where a diagnosis of NOE is suspected, although this may result in increased sensitivity of pick up, it ensures cases are not missed. Lambor stated  that any diabetic patient presenting with otalgia and otorrhoea should be deemed to have NOE until proven otherwise3. This concept has been adapted to define our patients with suspected NOE, along with findings from our retrospective case series and large scale patient demographic studies in the literature1,4. This is the evidence used to constitute our diagnostic criteria. In patients with a cranial nerve palsy, most commonly cranial nerve VII, and signs of ear infection the diagnosis should also be considered, however, this will often be a late presenting sign5. We also felt it prudent to include a failure to respond to one week of conservative treatment of otitis externa as a red flag sign to consider NOE .

On clinical review of patients with suspected NOE, microsuction should initially be undertaken for adequate assessment of the ear canal. At this stage swab samples of discharge should be sent for culture and sensitivity (C&S) – both routine and fungal, to determine the organisms involved and to guide antibiotic choice. Tissue samples of any granulation should be obtained and sent for both C&S and histopathology. This is important in the potential identification of organisms that may be missed from superficial swab cultures. Furthermore, alternative diagnoses such as squamous cell carcinoma of the ear canal can, rarely, present similarly to NOE and must be excluded6. There is evidence that C-Reactive Protein (CRP) is correlated with disease status (although our local audit findings do not support this) and therefore should be checked on admission7.  It is quoted that patients with good diabetic control do not progress to the more severe form of NOE with involvement of surrounding anatomical structures8. Therefore in patients with diabetes, particular attention should be placed on glycaemic control with measurement of HbA1c and serial monitoring of blood glucose. Referral to the diabetic specialist team for review of diabetic control therefore forms part of the management of NOE.

Regarding antimicrobial therapy, if there is a high level of clinical suspicion of NOE then empirical intravenous treatment should be commenced after microbiological sampling. Locally piperacillin-tazobactam is the first line therapy due to its efficacy against the most prevalent organisms in NOE, in particular Ps. aeruginosa.  Ceftazidime may be suitable for patients with a history of non-urticarial rash following penicillins, although the risk of diarrhoea due to Clostridium difficile is greater. A true penicillin allergy requires elucidation through careful history taking and if necessary patients can be referred for further investigations to our penicillin allergy clinic (the authors acknowledge this is not always available), or review on the ward by an Infection specialist. All antibiotics should be reviewed following the analysis of cultures and sensitivities.

From our retrospective data, a factor identified as having potential to improve patient outcomes, was the presence of a named consultant otologist responsible for decision making in individual patients. This enables a clear management plan to be followed and encourages accountability for a patient’s care. Furthermore they are best placed to ensure the correct condition is being pursued. Under inexperienced care the diagnosis can easily be confused for other conditions such as squamous cell carcinoma of the ear canal or external ear canal cholesteatoma.

The next area to consider is what happens when the patient has clinically suspected NOE but lacks radiological features of disease. As discussed, alternative diagnoses such as malignancy or cholesteatoma should be considered and ruled-out. Otherwise we would classify this under the ‘severe’ otitis externa category. These patients should be treated actively in the first instance with reviews at 48 hour intervals to determine response to treatment, as early NOE can be missed on imaging9. Experience has shown that if risk factors for NOE are present and the patient is under treated, there is a potential for the condition to develop into osteomyelitis of the temporal bone10.

Those with diagnosed NOE undergo an induction 2 week course of intravenous antibiotics, in line with current practice of treating osteomyelitis at other sites, although this concept has recently been challenged11. A comprehensive re-assessment is required at this stage as a sub-optimal clinical recovery should prompt consideration of further tissue sampling, further scanning and a discussion with the infectious disease team/microbiologist regarding the appropriateness of chosen antibiotics. At this time the surgeons may want to consider whether local debridement or incision and drainage might be a useful adjunct to treatment12. Indeed a body of evidence suggests that samples from this deep debridement may harvest fungal organisms that have not been identified on previous cultures13,14. Should a clinical improvement be observed, with no adverse clinical features present, and Ps.aeruginosa susceptible to ciprofloxacin has been isolated, then oral switch may be considered at this stage.  We would advocate the prescription of a subsequent 4 week course of ciprofloxacin 750mg every 12 hours, unless renal impairment present. Ciprofloxacin has excellent bone penetration; furthermore this allows the patient to be treated at home. Data from our audit looking at pseudomonal isolates supports ciprofloxacin as a valid option in the majority of patients. The caveats are that this could change with ongoing antibiotic pressure and sub-therapeutic doses being administered topically. Patients also require counselling on the risk of tendon inflammation/rupture, neurological complications, risk of ruptured aneurysm15 and the increased risk of Cl. difficile infection16. Patients should be monitored clinically until recovery is ensured with regular microsuction and examination of the external auditory canal. Following this we advocate patients receiving follow up with their named otologist at 4-6 weeks to ensure clinical recovery is sustained. However, regarding relapse, local data appear to be reassuring, with only 1 out of 20 cases relapsing following completion of treatment.

Clearly, avoiding progression of disease to severe NOE is essential. We classify severe NOE here as osteomyelitis of the petrous-temporal bone involving surrounding structures resulting in cranial nerve palsies, which once present, are usually irreversible and life altering. Indeed any patient suffering from NOE with cranial nerve involvement would be subject to at least 6 weeks of intravenous antipseudomonal antibiotics, furthermore patients that have received 2 weeks of intravenous antibiotics where we have not observed a sustained clinical recovery, or worse, seen progression of disease, would also be considered for a further 4 weeks of intravenous therapy. One issue remains that current intravenous antipseudomonal antibiotics require frequent dosing, precluding the use of many outpatient parenteral antibiotic therapy (OPAT) services. Consequently many patients are confined to hospital wards for this protracted period, which is poor for patient psychological health, as well as being a burden on a service where inpatient beds are increasingly under pressure. Our OPAT team has developed a service which facilitates training of family or care givers in administering intravenous antibiotics at home. This is offered in selected cases, whilst ensuring the patients receive regular review of their clinical status, particularly with regard to the appearances of the external auditory canal.

NOE caused by invasive fungal infection, usually Aspergillus species, is rare but must not be overlooked. These infections  often develop from the mastoid or middle ear and can be much more invasive. Consequently, identifying the pathogen early is essential. The gold standard involves testing for the presence of hyphae in tissue samples. Recognition that a single isolate of mould or yeast from a swab must not be considered an indication for prolonged systemic antifungal treatment is essential. If invasive infection with Aspergillus species is confirmed  then prolonged treatment (> 12 weeks) with voriconazole is advised17,18,19. This should be overseen by the local consulting Infection team with levels taken after 7 days or following any dose adjustment. Yeasts isolated from superficial swabs are not generally treated with antifungals, however, this finding should prompt consideration of deep tissue sampling to assess any requirement for systemic antifungal therapy. 

Evidence on topical antibiotics remains ambiguous and therefore our current guideline does not require specific topical treatment to be prescribed. Many ENT specialists advocate the use of topical treatment, and further work to look into the efficacy of this therapy is needed. 

A recent systematic review was conducted by J Phillips looking at the evidence for the use of hyperbaric oxygen therapy as an adjunct in NOE and it was found to be equivocal20. Therefore this has not been suggested as a therapeutic option in our guideline.

There is a paucity of evidence on surgical debridement with much discrepancy between studies with no common factors linking debridement to positive outcome12,21. We therefore concluded that this should be considered on a case by case basis by the patient’s named otologist. It is reasonable to suggest that local soft tissue debridement or incision and drainage of abscesses would be a useful therapeutic adjunct, particularly in patients whose progress appears to have stalled.

Imaging modality remains a point of contention. The bulk of the evidence suggests that contrast computed tomography (CT) of the petrous portion of the temporal bone should be used a gold standard for the detection of temporal bone osteomyelitis7,22 due to sensitivity, ease of access and cost-effectiveness. As a result this is our first-line radiological investigation. However, there is evidence to suggest that CT may miss early stages of disease and therefore we have reserved magnetic resonance imaging (MRI) for further clarification of disease extent in cases where clinical and radiological findings are incongruous9. From our own data we have observed a case where both CT and MRI were negative yet necrotic bone was excised on debridement. This episode precipitated  a large scale review of imaging modality and reporting. Good results are achieved with a dedicated ENT radiologist who is given the opportunity to meet regularly with the ENT surgical department and is given full clinical details (facilitated by radiology referrals being made by more senior members of the team).
 
Short-term Outcomes
Following the development of our protocol, prospective data is being collected to observe both adherence to our guidelines and monitoring of our patient outcomes to facilitate its adaptation over time. This unprecedented approach in combining different medical and surgical specialties in the creation of a NOE guideline has helped accommodate the different areas of expertise, offering a more holistic view of the patients care. Furthermore it enhances the working relationship between departments which should seek to optimise management. Our data tells us that 100% of cases are managed on the ENT wards with input from infectious disease and microbiology teams. Further to this, cases are also discussed at weekly infection multidisciplinary team (MDT) meetings and neuroradiology MDT meetings where outcomes are fed back to the patient’s team. Following patient progress and outcomes, as well as regularly considering and re-considering our definition, and  published best practice for this condition, is certainly a useful approach to enhance our understanding the condition.

Since the implementation of our guideline 14 cases, subsequent and separate to the initial data set, have been recorded through the department. With excellent adherence to our guidance, 2/14 cranial nerve palsies have been observed (one of which was already present from a previous episode) as well as 1/14 deaths within 3 months of diagnosis (to an unrelated condition). Ten out of 14 made a complete and sustained recovery at 4 week follow up post discharge, with the other patients either dying, suffering persistent cranial nerve palsies or relapsing. Clearly these numbers are small therefore it is difficult to draw any robust conclusions, however it does appear that early diagnosis and appropriate management of at-risk patients can result in positive outcomes. Some important messages drawn from the data include; all the patients had a named consultant otologist in charge of their care and patients with a HBA1c over 70mmol/mol (indicating poor glycaemic control) on admission had prompt referrals to diabetic nurse specialist for optimisation of blood glucose control. Although all the patients presented with clinical NOE, only 8/14 demonstrated bony erosion on imaging and thus met radiological criteria for NOE. Nonetheless all the patients received a minimum of 6 weeks of antibiotics, one of these was switched onto oral ciprofloxacin after 2 weeks of intravenous (IV) treatment. The question remains, are we now over diagnosing and overtreating? Are some patients being subjected to longer courses of treatment who would otherwise have made a full recovery? This possibility exists, to refute it more data are required to compare against our retrospective results as well as outcomes across other centres. Our rationale is that imaging may miss early osteitis or cartilaginous inflammation. This was demonstrated in one case of severe otitis externa with clinical features of NOE  with no radiological changes in keeping with NOE. Subsequent examination under anesthesia and debridement revealed necrotic cartilage and bone under the squamous epithelium of the ear canal, thus confirming a diagnosis of NOE.

Conclusion and further work
NOE is a condition that is increasing in incidence (ISD Scotland, direct communication)23. Moreover through local, as well as global evidence, we are continuously enhancing our understanding of the patient demographics, disease course and management of this serious condition. Creation of this guideline has drawn upon a body of evidence with the intention of optimising our management of NOE, ensuring that we avoid inadequate treatment thereby mitigating the risk serious complications.

With contention in the literature on a true definition of NOE, as well as challenges in its diagnosis, the clinical condition should be reviewed in stages and those at risk treated. We recognise there is a spectrum of disease, ranging from those patients that demonstrate risk factors or typical clinical signs on presentation, through to those with fulminant skull base osteomyelitis. Our recommendation is that it is imperative that patients who meet the clinical criteria are treated sufficiently to avoid progression to a more severe form of the disease. Following identification of these patients in primary care rapid access to ENT assessment clinics is important in order to start the investigation and management pathway early. 

As per our guideline there is opportunity for treatment to be de-escalated during the course of management should there be a notable change in circumstances. For example the scan demonstrates no evidence of bony involvement, and the patient’s symptoms respond rapidly to intravenous therapy. It is accepted that we may be over treating some patients, however undertreatment, resulting in serious complications must be avoided. A prospective review of our subsequent outcomes will be helpful in identifying these patients.

Going forward, further prospective data is being collected following the implementation of this guideline with the aim of assessing patient outcomes. This will help to validate our guideline and allow further refinements to optimise management of this challenging patient cohort.

The limitations of any clinical guidelines are the neglect of clinical experience and the heterogeneous manner in which condition present and progress. Therefore it has never been suggested that this flow chart should be strictly adhered to. It has been designed primarily to provide guidance and ensure that even experienced clinicians are not missing salient aspects of the patient’s management. 
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Summary Sheet:
 Necrotising otitis externa presents with severe otalgia, otorrhoea and granulation tissue in the external auditory canal; cranial nerve palsies indicate advanced disease
 Risk factors include old age, poor diabetic control and immunocompromise
 There is variation in necrotising otitis externa management between centres, due to its heterogeneous nature and lack of robust evidence for treatment
 This paper presents the first published NHS health board based guideline for necrotising otitis externa management
 The protocol integrates local data, an up-to-date evidence base and a multi-specialty approach
 Necrotising otitis externa represents a spectrum of disease; avoiding under-treatment may prevent disease progression and relapse



















Figure I. NHS Lothian guideline for diagnosis and management of Necrotising Otitis Externa
NOE = Necrotising Otitis Externa, DM = Diabetes Mellitus, IC = Immunocompromise, Tx = Treatment, C&S = Culture and Sensitivity ID = Infectious Disease, OPAT = Outpatient Parenteral Antibiotic Therapy, OE = Otitis Externa, Glu = Glucose, PICC  = Peripherally Inserted Central Catheter, EUA = Examination Under Anesthesia, BM = blood glucose measurement, Abx = Antibiotic
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Tables

Table 1. Signs and symptoms*
Signs & symptoms	Cases (n)
Severe otalgia	20
Otorrhoea 	19
Granulation tissue within ear canal	17
Cranial nerve palsy	5
Total n = 20. *In patients with radiologically proven necrotising otitis externa from our retrospective case series.

Table 2. Demographic data*
Patient demographics	Cases (n)
Diabetic	13
Age >65 years	17
Previous ear surgery	5
Immunosuppressed	1
Hearing aid user	15
Total n = 20. *For patients with radiologically proven necrotising otitis externa from our retrospective case series.

Table 3. Organisms cultured*
Organisms cultured 	Cases (n)
Pseudomonas aeruginosa	12
Staphylococcus aureus	5
Aspergillus flavus	1
Yeast	6
No growth or normal skin flora	4
Total n = 20. *In patients with radiologically proven necrotising otitis externa from our retrospective case series.










